Regenexx Corporate
Regenexx Corporate sells non-surgical interventional orthopedic procedures (bone marrow concentrate and platelet-based injections) as a covered benefit to self-funded employers, brokers, and TPAs, capturing a share of the orthopedic surgical spend it helps clients avoid.
- Company typePrivate
- Founded2015
- HeadquartersDes Moines, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Regenexx Corporate does
Regenexx Corporate is a privately held healthcare company, headquartered in Des Moines, Iowa, that sells non-surgical interventional orthopedic procedures as a covered benefit under self-funded employer health plans. The company markets to self-funded employers (100+ employees), benefits brokers, and third-party administrators (TPAs), positioning its bone marrow concentrate (BMC) and platelet-based procedures — delivered via precisely guided, needle-based, image-guided injections — as a lower-cost alternative to orthopedic surgery for joint and soft tissue conditions.
Its core technology stack is anchored by proprietary devices and treatment methods protected by 24 issued patents and supported by what the company describes as the world's largest human mesenchymal stem cell re-implantation registry. Product portfolio includes the Regenexx Corporate Program (the employer-facing benefit), a Live Patient Outcomes Database (transparency/credibility tool), a Savings Calculator, a Benefits Card employee education tool, a Best-Practices Utilization Model for onboarding and steerage, and the Regenexx Physician Network — a nationwide footprint of 60+ board-certified interventional orthopedics physicians trained through the Interventional Orthopedics Foundation.
Regenexx operates a transactional, savings-share revenue model: rather than charging per procedure, the company captures a percentage of the orthopedic surgical spend it helps the employer avoid, functioning as a cost-plus arrangement tied directly to documented MSK savings. Distribution runs through a direct field sales team targeting self-funded employers, supplemented by channel partnerships with major brokerages (Hylant, Hub International, Gilsbar, Relph Benefit Advisors) and implementation support from consulting partner ACAP Health. Customer-reported outcomes cite 50–70% MSK spend reduction, 90%+ surgery-avoidance rates, and over $100 million in cumulative client healthcare savings across 2,000+ employer clients.
Regenexx Corporate firmographics
Firmographics- Name
- Regenexx Corporate
- Legal name
- Regenerative Sciences
- Website
- https://regenexxcorporate.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Regenexx Corporate sells non-surgical interventional orthopedic procedures (bone marrow concentrate and platelet-based injections) as a covered benefit to self-funded employers, brokers, and TPAs, capturing a share of the orthopedic surgical spend it helps clients avoid.
- Ownership category
- akta.pro rank
Regenexx Corporate industry classification
Industry- Product category
- Interventional Orthopedics Services
- NAICS
- Offices of Physicians (62111)
- SIC
- Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
Keywords
Where Regenexx Corporate is headquartered
LocationHeadquarters
- HQ city
- Des Moines
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Regenexx Corporate business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Orthopedic Benefit Cost Reduction: Regenexx generates revenue as a covered health benefit under employer self-funded health plans. The company charges based on a percentage reduction in orthopedic surgical spending for self-funded employers, functioning as a cost-plus or savings-sharing model rather than a per-procedure fee.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Regenexx Corporate product offering
Product offeringCore offering
Regenexx Corporate offers non-surgical interventional orthopedic procedures—primarily bone marrow concentrate and platelet-based treatments delivered via precisely guided, needle-based injections—as a covered health benefit for self-funded employers. The company operates a network of 50+ clinics staffed by 60+ certified physicians and charges employers based on a percentage of orthopedic cost reduction, functioning as a savings-sharing rather than per-procedure fee model.
Product overview
Regenexx Corporate offers a unified employer benefit program built around its core Regenexx Procedures — patented, FDA-compliant bone marrow concentrate and platelet-based treatments that serve as non-surgical alternatives to orthopedic surgery. The portfolio centers on the Regenexx Corporate Program, which employers add to self-funded health plans to reduce orthopedic spend by up to 80%. Supporting the core procedures are several modules: the Regenexx Benefits Card (employee education tool), the Savings Calculator (employer ROI estimation), the Live Patient Outcomes Database (transparency/credibility), and the Best-Practices Utilization Model (onboarding and steerage framework). The company also operates a nationwide Regenexx Physician Network of 60+ certified clinics delivering standardized procedures, supported by an internal R&D division conducting clinical research and machine learning-based outcome prediction. Together, these components form a vertically integrated platform: employer-facing program delivery, network clinic operations, patient outcome tracking, and ongoing research development.
Differentiator
Problem solved
Functional benefit
Products and services
- Regenexx Corporate Program A self-funded employer benefit program that provides non-surgical interventional orthopedic procedures as an alternative to traditional orthopedic surgery, helping employers reduce healthcare costs by up to 80%.
- Regenexx Procedures Patented, FDA-compliant bone marrow concentrate and platelet-based procedures that treat orthopedic conditions through minimally invasive, needle-based injections guided by imaging technology.
- Regenexx Physician Network A nationwide network of over 60 board-certified physicians specializing in interventional orthopedics, trained and certified through the Interventional Orthopedics Foundation, providing standardized procedures across clinic locations.
- Regenexx Best-Practices Utilization Model A comprehensive onboarding and implementation framework including education tools, incentive programs, step therapy practices, and steerage strategies to maximize employee utilization and cost savings.
Quantifiable outcome
- Reduces MSK spending by 50-70%
- +4 more outcomes
Companies that use Regenexx Corporate
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
Regenexx Corporate technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Regenexx Corporate partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Hub InternationalcorePartnership with Hub International, a leading insurance brokerage, to reduce orthopedic surgery costs for their self-funded employer clients through the Regenexx orthopedic benefit program.
- GilsbarcorePartnership with Gilsbar to provide Regenexx orthopedic procedures as a cost-reduction benefit for self-funded employer health plans.
- HylantcoreHylant, an insurance brokerage firm, has partnered with Regenexx to offer their employer clients access to non-surgical orthopedic procedures as a covered health benefit.
- ACAP HealthcoreACAP Health serves as a consulting partner, featuring CEO interviews and helping facilitate implementation of the Regenexx orthopedic benefit program with employers.
- Relph Benefit Advisors (The Alera Group)minorBenefits advisor relationship with Relph Benefit Advisors, part of The Alera Group, featured in interviews discussing the Regenexx program.
- Pulse Health SolutionsminorBenefits advisor relationship with Pulse Health Solutions, featured in interviews discussing the Regenexx program for employer health benefits.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Regenexx Corporate competitors and assessment
Company assessmentBroad incumbents
- Organogenesis: Organogenesis is an established regenerative medicine company selling wound and soft-tissue biologic products into surgical and outpatient channels, providing a relevant broader incumbent comparable in regenerative biologics.
- Stryker: Stryker's orthopedic and surgical equipment divisions serve the same hospitals, ambulatory surgery centers, and surgeons that anchor the conventional orthopedic pathway Regenexx's employer benefit is designed to bypass.
- Zimmer Biomet: Zimmer Biomet is a global orthopedic medical device leader whose joint reconstruction and sports medicine franchises define the surgical standard Regenexx positions against as a non-surgical alternative.
- Vericel: Vericel is a commercial-stage regenerative medicine company selling cell therapy products (MACI, Epicel) into orthopedic and sports medicine indications, making it a comparable but broader regenerative medicine incumbent rather than a direct employer-benefit competitor.
Direct peers
- InGeneron: InGeneron develops autologous regenerative cell therapies for orthopedic and other musculoskeletal indications, overlapping directly with Regenexx's bone marrow concentrate and platelet-based orthobiologics technology.
- Kaia Health: Kaia Health provides digital MSK and chronic pain management programs marketed to employers and payers, competing for the same self-funded employer benefit dollar with a software-delivered alternative to in-person orthopedic care.
- Hinge Health: Hinge Health sells a digital MSK care program to self-funded employers as a covered benefit, competing head-on with Regenexx for HR and broker mindshare in the orthopedic benefit category, though its modality is virtual exercise therapy rather than in-clinic orthobiologics.
- Sword Health: Sword Health offers virtual MSK and pelvic health programs sold through employer benefits and health plans, going after the same self-funded employer buyers as Regenexx with a digital-first delivery model.
Emerging players
- Mesoblast: Mesoblast develops cellular medicines for inflammatory and musculoskeletal conditions, an emerging regenerative medicine player whose orthopedic pipeline overlaps conceptually with Regenexx's bone marrow concentrate approach.
- Personalized Stem Cells: Personalized Stem Cells is an early-stage company developing autologous stem cell therapies for orthopedic indications, making it an emerging direct competitor in the regenerative orthopedics space where Regenexx already operates.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Regenexx Corporate social profiles
Digital presenceRegenexx Corporate compliance and trust
Trust signalCompliance2 records
Regenexx Corporate financial estimates
Financial estimateRevenue estimate
Valuation estimate
Regenexx Corporate leadership team
Management profileNumber of profiles
Profiles5 records
Regenexx Corporate funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Regenexx Corporate M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Regenexx Corporate
What does Regenexx Corporate do?
Regenexx Corporate offers non-surgical interventional orthopedic procedures—primarily bone marrow concentrate and platelet-based treatments delivered via precisely guided, needle-based injections—as a covered health benefit for self-funded employers. The company operates a network of 50+ clinics staffed by 60+ certified physicians and charges employers based on a percentage of orthopedic cost reduction, functioning as a savings-sharing rather than per-procedure fee model.
Is Regenexx Corporate a public or private company?
Regenexx Corporate is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Regenexx Corporate founded?
Regenexx Corporate was founded in 2015. It employs 251 to 500 people.
Where is Regenexx Corporate based?
Regenexx Corporate is headquartered in Des Moines, United States, in the North America region.
How does Regenexx Corporate make money?
One revenue line is on record: orthopedic Benefit Cost Reduction.
Who are Regenexx Corporate's main competitors?
Broad incumbents on record are Organogenesis, Stryker, Zimmer Biomet and Vericel. Direct peers are InGeneron, Kaia Health, Hinge Health and Sword Health. Emerging players are Mesoblast and Personalized Stem Cells.
Does Regenexx Corporate have an API?
No public API is recorded for Regenexx Corporate.
What industry is Regenexx Corporate in?
Regenexx Corporate's product category is Interventional Orthopedics Services. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 62111 and its SIC code is 8000.